Table Of ContentRepublic of Ghana
Standard Treatment 
Guidelines
Ministry of Health 
Sixth Edition, 2010
© 2010 Ministry of Health (GNDP) Ghana
All rights reserved. No part of this publication may be reproduced, stored in 
a retrieval system, or transmitted in any form or by any means, electronic, 
mechanical, photocopying, recording and/or otherwise, without prior 
written permission of the Ministry of Health, Ghana
st
Essential Drugs List & National Formulary with Therapeutic Guidelines, 1 
Edition, 1988
nd
Essential Drugs List & National Formulary with Therapeutic Guidelines, 2 
Edition, 1993
rd
Essential Drugs List & National Formulary with Therapeutic Guidelines, 3 
Edition, 1996
Standard Treatment Guidelines, 4th Edition, 2000
Standard Treatment Guidelines, 5th Edition, 2004
Standard Treatment Guidelines, 6th Edition, 2010
ISBN    978-9988-1-2538-7
For all enquiries write to the publishers:
Ghana National Drugs Programme (GNDP)
Ministry of Health
P. O. Box MB-582, Accra, Ghana, West Africa
Tel: (0)30 2661 670/1    
Fax: (0)30 2664 309
E-mail:
LIST OF TABLES
Table 2-1: Assessment of the degree of dehydration in children with diarrhoea
Table 2-2:  Treatment by Fluid therapy- Plan A
Table 2-3: Treatment by Fluid therapy- Plan B
Table 2-4: Treatment by Fluid therapy- Plan C
Table 2-5:  Helicobacter pylori Eradication Therapy
Table 5-1:  Pain Management in the Sickle Cell Patient
Table 6-1:  Schedule for Immunization for Children
Table 8-1:  Antihypertensive Treatment by Drug Class
Table 8-2:  New York Heart Association functional Classification for Heart Failure
Table 10-1:  Drug Treatment of Seizures
Table 10-2:  Guidelines for the Management of the Unconscious Patient
Table 12-1:  Guidelines for the Treatment of Itching of specific causes
Table 13-1:  Regime for managing Diabetic Ketoacidosis in Adults
Table 13-2:   Regime for managing diabetic Ketoacidosis in Children
Table 13-3:   Example of Sliding Scale Chart
Table 15-1:  Misoprostol Dosages for Reproductive Health
Table 16-1: Classification for Acute Kidney Injury, based on modification of 
RIFLE  criteria
Table 16-2 :  Causes of Male Infertility
Table 16-3:  Symptoms and Signs of Urinary Tract Calculi
Table 16-4:  Distinguishing between Torsion and Epididymoorchitis
Table 19-1:  Guidelines for the Treatment of the Patient with Fever
Table 19-2: Empirical Antibiotic Therapy for suspected Bacterial Meningitis in  Adults
Table 19-3:  Artesunate + Amodiaquine Co-Blistered Tablets (Regimen for once daily 
dosing)
Table 19-4:  Artesunate and Amodiaquine Co-Blistered Tablets (Regimen for twice 
daily dosing)
Table 19-5:   Artesunate and Amodiaquine Fixed Dose Combination. 
  (Standard Regimen, using the 3 available dosing strengths)
Table 19-6:  Artemether and Lumefantrine (Recommended Dosing Regimen)
Table 19-7:   Dihydroartemisinin and Piperaquine (Recommended Dosing Regimen)
Table 19-8:   Dosing Regimen for Quinine IM Injection in young Children
Table 19-9:   Rectal Artesunate (Pre-Referral Treatment in Children)
Table 19-10:Rectal Artesunate (Pre-Referral Treatment in Adults)
Table 19-11:Pharmacological Treatment of Worm Infestations
Table 20-1:  Dose of Vitamin A for Xerophthalmia
Table 20-2:   Characterising Acute Red Eye with no history of Injury
Table 20-3:   Summary of the Common Causes and Management of Conjunctivitis
Table 23-1: Points of distinction between Inflammatory and Mechanical Back Pain
Table 24-1:  Indication for use of Rabies Immunoglobulin and Rabies vaccine
Table 26-1:  Choice of Antibiotic for Prophylaxis
vii
PREFACE 
Standard Treatment Guidelines (STG) are systematically developed 
statements that assist prescribers in deciding on appropriate treatments for 
specific clinical problems. They usually reflect the consensus on the optimal 
treatment options within a health system and aim at beneficially influencing 
prescribing behaviour at all levels of care. 
Health systems, particularly in developing countries, are faced with 
growing health needs on one hand and limited resources on the other. Policy 
makers at various levels are therefore engaged in designing cost-effective 
health interventions that ensure accessible and affordable quality care for 
all, in particular the poor and vulnerable groups. 
Inappropriate prescribing is one of the manifestations of irrational 
medication use behaviour. It occurs when medicines are not prescribed in 
accordance with guidelines that are based on scientific evidence to ensure 
safe, effective, and economic use. STGs provide the tool for health care 
providers to give quality standardised care at affordable cost.
For our growing National Health Insurance Scheme, a standard 
treatment guideline is seen as a cost containment tool to ensure that 
inefficiencies, fraud and poly-pharmacy, often associated with Health 
Insurance Schemes, are minimised.
Regular, objective and transparent reviews of STGs are very important 
because the development process is a continual effort and not limited to a 
one-time production. This process includes gaining acceptance of the 
concept and preparing the text for wide consultation and consensus 
building. This is to ensure that users identify with and collectively own the 
process of development. 
This document is the sixth edition of the Ministry of Health's officially 
approved prescribers' and dispensers' guide for all levels of healthcare. 
Great effort has been put into aligning the prevailing health insurance 
benefits package to this edition.This edition is also available on compact disk 
and can be accessed on the internet at www.ghndp.org.
The Ministry of Health is particularly grateful to its development 
partners for their continuous support for the health sector. 
I am confident that all users of this document would find this edition 
very useful.
Dr. Benjamin Kunbuor
Hon. Minister for Health
May, 2010
viii
IMPORTANT CONTACTS 
• PHARMACOVIGILANCE UNIT, FOOD AND DRUGS BOARD
Adverse drug reactions: Please report any adverse drug reactions to 
the Pharmacovigilance Unit of the Food and Drugs Board (FDB).
Telephone number:  030- 2229 621, 030-2233 200, 030-2235 100,
          030-2225 502
Fax number:           030- 2229 794 
Website:  www.fdbghana.gov.gh
• NATIONAL AIDS CONTROL PROGRAMME (NACP)
Telephone number:  030-2662 691
• NATIONAL AMBULANCE SERVICES
Telephone number:  030-2684 201, 030-2684 251, 030-2684 259
• NATIONAL DRUG INFORMATION RESOURCE CENTRE
Telephone number:  030-2678 557, 030-2678 559
Fax number:           030-2678 557
Website:  www.ghanadruginformation.org
• NATIONAL POISONS CONTROL CENTRE
Telephone number: 030-2238 636, 030-2243 552
• NATIONAL BURULI  ULCER CONTROL PROGRAMME
Telephone  number:  030-2686 337
Fax number:            030-2686 336
Website:  www.burulighana.org
• GHANA POLICE SERVICE
Telephone number:  191,  999,  027-7522 288
Website:  www.ghanapolice.info
Comments and suggestions should be sent to:
The Programme Manager
Ghana National Drugs Programme
Ministry of Health
P.O. Box MB-582, Accra, Ghana
Telephone number:  (0) 30 2661 670/1
Fax number: (0) 30 2664 309
E-mail:
ACKNOWLEDGEMENT
The review of the Standard Treatment Guidelines 2010 by the Ministry of 
Health / Ghana Health service and its agencies has been successfully 
completed as a result of the recommendations and contributions received 
from:
MOH/GHS/School of Medicine and Pharmacy Executives
Dr. B. Kunbuor Hon. Minister of Health 
Dr. Elias K. Sory Director General, Ghana Health 
Service (GHS)
Dr. Sylvester D. Anemana Ag. Chief Director, MOH
Mr. James Ohemeng Kyei Chief Pharmacist, GHS/MOH
Mr. George Dakpalah Director, Policy Planning Monitoring 
and Evaluation (PPME), MOH
Mr. Samuel Boateng Director, Ministry of Health (MOH)
Dr. Cynthia Bannerman Institutional Care Division, GHS
Mrs. Freda Bartels Mensah Ag. Director, Procurement and Supplies, 
MOH.
Mr. Sylvester Mensah CEO, National Health Insurance Authority
Dr. Akwasi Osei Chief Psychiatrist, GHS
Dr. (Mrs.) G. Quansah Asare  Director, Family Health, GHS
Prof. Nii Otu Nartey CEO, Korle Bu Teaching Hospital (KBTH)
Prof. Ohene Adjei CEO, Komfo Anokye Teaching Hospital
 (KATH)
Prof. (Mrs.) C. Ntim Amponsah   Dean, University of Ghana Medical School 
      (UGMS)
Prof. Kwabena Danso Dean, School of Medical Sciences (SMS), 
Kwame Nkrumah University of Science 
and Technology (KNUST)
Prof. Mahama Duwiejua Dean, Faculty of Pharmacy and
Pharmaceutical Sciences, KNUST
Mrs. Joycelyn Azeez Head, Procurement Unit, MOH
Mr. Peter Ekow Gyimah Head, Central Medical Stores, MOH
Expert Committee Members
Dr. F. Ofei (Chairman)  Department of Medicine and
Therapeutics, UGMS
Dr. K. Aboah Department of Surgery, SMS, KNUST
Dr. A. Akpalu Department of Medicine, KBTH
Mr. P. Anum National Drugs Information Centre, 
Pharmacy Council
Dr. K. Aryee Department of Obstetrics and
Gynaecology, UGMS
Dr. J.N. Clegg-Lamptey Department of Surgery, UGMS
Dr. A.N.O. Dodoo Centre for Tropical Clinical Pharmacology 
and Therapeutics, UGMS
Dr. (Mrs.) I. Ekem Department of Haematology, UGMS
x
ACKNOWLEDGEMENTS
Dr. (Mrs.) A. Forson Department of Medicine and
Therapeutics, UGMS
Prof. E. H. Frimpong Department of Medical Microbiology,
 SMS, KNUST
Dr. E. D. Kitcher Department of Surgery, UGMS
Prof. G. Klufio Department of Surgery, UGMS
Prof. M. O. Mate-Kole Department of Medicine and
Therapeutics, UGMS
Mr. A. Mensah Department of Pharmacy, KATH
Prof. S. Naaeder Department of Surgery, UGMS
Mrs. Amah Nkansah Department of Pharmacy, KBTH
Prof. H. Addo Department of Medicine and
Therapeutics, UGMS
Dr. (Mrs.) E. Ofori-Adjei University Health Services, University of
 Ghana
Dr. S. Ohene Department of Psychiatry, UGMS
Dr. I. Owusu Department of Medicine, SMS, KNUST
Prof. (Mrs.) B. Quarm Goka Department of Child Health, UGMS
Mr. R. Tetteh Department of Pharmacy, KBTH
Prof. (Mrs.) J. Welbeck Department of Child Health, UGMS
Editorial Committee Members
Dr. F. Ofei  (Chairman) Department of Medicine and
Therapeutics, UGMS
Dr. A. Akpalu Department of Medicine, KBTH
Dr. A.N.O. Dodoo  Centre for Tropical Clinical Pharmacology 
and  Therapeutics, UGMS
Mrs. Martha Gyansa-Lutterodt  Ghana National Drugs Programme, MOH
Mrs. Amah Nkansah Department of Pharmacy, KBTH
Prof. (Mrs.) J. Welbeck Department of Child Health, UGMS
Coordinators
Mrs. Augustina Koduah Ghana National Drugs Programme, MOH
Mr. Brian Adu Asare Ghana National Drugs Programme, MOH
Programme Managers
Dr. P. Aboagye Reproductive Health Unit, GHS
Dr. N.A. Addo National AIDS/STI Control Programme
 (NACP)
Dr. K.O. Antwi-Agyei Expanded Programme on Immunization
 (EPI), GHS
Dr. (Mrs.) C. Bart-Plange National Malaria Control Programme
 (NMCP), GHS
Dr. F. Bonsu National Tuberculosis Programme.
(NTP), GHS
xi
ACKNOWLEDGEMENTS
Dr. O. Debrah  Eyecare Programme, GHS
Dr. Agana Nsiire National Yaws Eradication Programme
 (NYEP)
Dr. S. Kyei Faried Head, Disease Control Unit, GHS
Dr. (Mrs.) I. Sagoe-Moses   Child Health, GHS
Dr. Yaa Osei Family Planning, GHS
World Health Organisation (WHO)
Dr. Daniel Kertesz Country Representative, Ghana
Mrs. Edith Andrews-Annan National Professional Officer, Essential
  Drugs and  Medicines Policy, Ghana
Management Sciences for Health
Mr. Kwesi Eghan Country Representative, MSH/SPS/USAID
Ghana National Drugs Programme 
Mrs. Martha Gyansa-Lutterodt    Programme Manager
Mrs. Augustina Koduah Assistant Programme Manager
Mr. Brian Adu Asare Programme Officer
Mrs. Stella A. Ntow Principal Programme Accountant
Mr. Joshua Y. Quarshie Accountant
Agnes Osei Konadu Account Officer
Mrs. Mispah Afram Office Manager
Diana Edusei Front Desk Manager
The Royal Netherlands Government
for their support to the Ghana National Drugs Programme (GNDP)
GNDP Steering Committee
Mr. Robert Joseph Mettle-Nunoo Hon. Deputy Minister, Ministry of Health 
Dr. Sylvester D. Anemana  Ag. Chief Director, MOH
Dr. Elias K. Sory Director General, GHS 
Mr. James Ohemeng Kyei Chief Pharmacist, MOH/GHS
Mr. T.C.P. Corquaye  Ag. Chairman, Food & Drugs Board
Mr. David Anim Addo  Chairman, Pharmacy Council
Mrs. Freda Bartels Mensah Ag. Director, Procurement and Supplies, 
MOH
Mr. F. Dakpallah  Director, PPME, Ministry of Health
Prof. David Ofori-Adjei  University of Ghana Medical School
Mr. Herman Dusu  Financial Controller, MOH
Dr. (Mrs.) I. Agyepong  Regional Director of Health Services, 
Greater Accra Region
Prof. Mahama Duwiejua Dean, Faculty of Pharmacy and
Pharmaceutical Sciences, KNUST
Mrs. Martha Gyansa-Lutterodt  Programme Manager, GNDP/MOH
xii
CHAPTER 1:  INTRODUCTION
The Government of Ghana, through the National Drug Policy, remains 
committed to ensuring the availability of, and accessibility to affordable and 
good quality medicines for all Ghanaians; and it is expected that these 
medicines would be used rationally. Achieving these objectives require a 
comprehensive strategy that, not only includes supply and distribution, but 
also appropriate and thoughtful prescribing, dispensing and use of 
medicines.
The Ministry of Health since 1983 has been publishing a list of Essential 
Drugs with Therapeutic Guidelines to aid the rational use of drugs. This 
document has been reviewed in response to new knowledge on drugs and 
diseases and changes in the epidemiology of diseases in Ghana. The 
Ministry has also produced separate guidelines for specific disease control 
programmes, diseases and identifiable health providers.
The Standard Treatment Guidelines have been prepared as a tool to 
assist and guide prescribers (including doctors, medical assistants, and 
midwives), pharmacists, dispensers, and other healthcare staff who 
prescribe at primary care facilities in providing quality care to patients. The 
guidelines list the preferred treatments for common health problems 
experienced by people in the health system and were subjected to 
stakeholder discussions before being finalised to ensure that the opinion of 
the intended users were considered and incorporated.
The guidelines are designed to be used as a guide to treatment choices 
and as a reference book to help in the overall management of patients, such 
as when to refer. The guidelines are meant for use at all levels within the 
health system, both public and private.
It is recognised that the treatment guidance detailed in this book may 
differ from the reader’s current practice. It is emphasised that the choices 
described here have the weight of scientific evidence to support them, 
together with the collective opinion of a wide group of recognised national 
and international experts. The recommendations have been rated on the 
following basis:
Evidence rating A – requires at least one randomised control trial as 
part of a body of scientific literature of overall good quality and consistency 
addressing the specific recommendation.
Evidence rating B – requires the availability of well-conducted clinical 
studies but no randomised clinical trials on the topic of recommendation.
Evidence rating C – requires evidence obtained from expert committee 
reports or opinions and/or clinical experience of respected authorities. This 
indicates an absence of directly applicable clinical studies of good quality.
Treatments other than those recommended here may have to be 
justified to colleagues, managers, or in law.
13
The content of these treatment guidelines will undergo a process of 
continuous review. Comments or suggestions for improvement are 
welcome. 
Those comments or suggestions for addition of diseases should include 
evidence of prevalence as well as a draft treatment guideline using the 
format set out in this book. In the case of a request for a new drug or 
replacing a listed product with another product, the evidence base must be 
clearly defined and included with the request.
These suggestions should be sent to:
The Programme Manager
Ghana National Drugs Programme
Ministry of Health
P.O. Box MB-582, Accra, Ghana
West Africa
Website: www.ghndp.org
      HOW TO USE THIS BOOK
To use these guidelines effectively, it is important that you become 
familiar with the contents and layout.
The contents of this book have as much as possible been arranged in 
order of 'body systems'. Within each section, a number of disease states 
which are significant in Ghana have been identified. For each of these 
disease states the information and guidance has been standardised to 
include a brief description of the condition or disease and the more 
common symptoms and signs. In each case the objectives of treatment have 
been set out, followed by recommended non-pharmacological as well as the 
pharmacological treatment choices.
The choice of treatment used here is based on the principles of 
'evidence based medicine'. That is, it is based on the international medical 
and pharmaceutical literature, which clearly demonstrates the efficacy of 
the treatment choices.
The treatment guidelines try to take the user through a sequence of 
diagnosis, treatment, treatment objectives, and choice of treatment and 
review of outcome. It is strongly recommended that prescribers adopt a 
similar approach to practice. Care should be taken to avoid symptomatic 
management of uncertain diagnoses.
When treating patients, the final responsibility for the well being of the 
individual patient remains with the prescriber. Prescribers must take steps 
to ensure that they are competent to manage the most common conditions
14